07-822 Anti-phospho-eIF2Bε (Ser539) Antibody

100 µL  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Special Offers


      Contact Customer Service

      Click To Print This Page


      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H, RWBRbAffinity PurifiedPolyclonal Antibody
      Catalogue Number07-822
      Brand Family Upstate
      Trade Name
      • Upstate
      DescriptionAnti-phospho-eIF2Bε (Ser539) Antibody
      Product Information
      FormatAffinity Purified
      ApplicationAnti-phospho-eIF2Bε (Ser539) Antibody is an antibody against phospho-eIF2Bε (Ser539) for use in WB.
      Key Applications
      • Western Blotting
      Biological Information
      ImmunogenKLH conjugated synthetic peptide corresponding to amino acids surrounding Ser539 of human eIF2Bε
      SpecificityRecognizes eIFB2ε phosphorylated on Ser539.
      Species Reactivity
      • Human
      • Rat
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Gene Symbol
      • EIF2B5
      • EIF-2B
      • EIF2Bepsilon
      • LVWM
      • EIF2BE
      • CLE
      • CACH
      • Phosphorylation
      Purification MethodImmunoAffinity Purified
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: Q13144 # Catalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP.
      SIZE: 721 amino acids; 80380 Da
      SUBUNIT: Complex of five different subunits; alpha, beta, gamma, delta and epsilon.
      DISEASE: SwissProt: Q13144 # Defects in EIF2B5 are a cause of leukoencephalopathy with vanishing white matter (VWM) [MIM:603896]. VWM is a brain disease that occurs mainly in children. The neurological signs of VWM include progressive cerebellar ataxia, spasticity, inconstant optic atrophy and relatively preserved mental abilities. The disease is chronic-progressive with, in most individuals, additional episodes of rapid deterioration following febrile infections or minor head trauma. Head trauma leads only to motor deterioration, whereas infections with fever may end in coma. Death occurs after a variable period of a few years to a few decades, usually following an episode of fever and coma. & Defects in EIF2B5 are a cause of ovarioleukodystrophy [MIM:603896]; also known as vanishing white matter leukodystrophy with ovarian failure. It is a condition of ovarian failure associated with cerebral abnormalities similar to those in patients with vanishing white matter leukodystrophy. & Defects in EIF2B5 are a cause of Cree leukoencephalopathy (CLE) [MIM:603896]. CLE is a rapidly fatal infantile autosomal recessive leukodystrophy that is observed in the native Cree and Chippewayan indigenous population of northern Quebec and Manitoba.
      SIMILARITY: SwissProt: Q13144 ## Belongs to the EIF-2B gamma/epsilon subunits family.
      Molecular Weight82 kDa
      Physicochemical Information
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceRoutinely evaluated by immunoblot.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Packaging Information
      Material Size100 µL
      Transport Information
      Supplemental Information




      Safety Data Sheet (SDS) 

      Certificates of Analysis

      TitleLot Number
      Anti-phospho-eIF2Be (Ser539) (Affinity Purified Rabbit Polyclonal IgG) - 22916162291616
      Anti-phospho-eIF2Be (Ser539) (Affinity Purified Rabbit Polyclonal IgG) - DAM1467542DAM1467542
      Anti-phospho-elF2Bε (Ser539)3126681
      Anti-phospho-elF2Bε (Ser539) -27261202726120
      Anti-phospho-elF2B (Ser539) - 25580762558076
      RABBIT ANTI-eIF2Bε (pS539) -27165672716567
      anti-phospho-eIF2Bepsilon; (Ser539) - 06040273820604027382
      anti-phospho-eIF2Bepsilon; (Ser539) - 07010496470701049647
      anti-phospho-eIF2Bepsilon; (Ser539) - JBC1371258JBC1371258


      Reference overviewPub Med ID
      PKR and GCN2 kinases and guanine nucleotide exchange factor eukaryotic translation initiation factor 2B (eIF2B) recognize overlapping surfaces on eIF2alpha.
      Dey, Madhusudan, et al.
      Mol. Cell. Biol., 25: 3063-75 (2005)  2005

      Show Abstract
      15798194 15798194
      Dynamic cycling of eIF2 through a large eIF2B-containing cytoplasmic body: implications for translation control
      Campbell, S.G. et al.
      J. Cell Biol., 170(6):925-934 (2005)  2005

      16157703 16157703
      Phosphorylation of eukaryotic initiation factor eIF2Bepsilon in skeletal muscle during sepsis
      Vary, Thomas C, et al
      Am J Physiol Endocrinol Metab, 283:E1032-9 (2002)  2002

      12376332 12376332
      The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase
      Woods, Y L, et al
      Biochem J, 355:609-15 (2001)  2001

      11311121 11311121
      Eukaryotic initiation factor 2B: identification of multiple phosphorylation sites in the epsilon-subunit and their functions in vivo
      Wang, X, et al
      EMBO J, 20:4349-59 (2001)  2001

      11500362 11500362
      The activation of eukaryotic initiation factor (eIF)2B by growth factors in PC12 cells requires MEK/ERK signalling
      Kleijn, M and Proud, C G
      FEBS Lett, 476:262-5 (2000)  2000

      10913625 10913625
      Glycogen synthase kinase-3 is the predominant insulin-regulated eukaryotic initiation factor 2B kinase in skeletal muscle
      Jefferson, L S, et al
      Int J Biochem Cell Biol, 31:191-200 (1999)  1999

      10216953 10216953
      Identification of interprotein interactions between the subunits of eukaryotic initiation factors eIF2 and eIF2B
      Kimball, S R, et al
      J Biol Chem, 273:3039-44 (1998)  1998

      9446619 9446619
      T-cell activation leads to rapid stimulation of translation initiation factor eIF2B and inactivation of glycogen synthase kinase-3.
      Welsh, G I, et al.
      J. Biol. Chem., 271: 11410-3 (1996)  1996

      Show Abstract
      8626696 8626696
      The guanine nucleotide-exchange factor, eIF-2B
      Price, N and Proud, C
      Biochimie, 76:748-60 (1994)  1994

      7893825 7893825


      RNA-Binding Protein Immunoprecipitation